News | April 10, 2023
Thermo Fisher Scientific expands its capabilities in France
Bourgoin early development hub broadens offerings for oral solid dose formulations
Bourgoin early development hub broadens offerings for oral solid dose formulations
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
The facility is over 79,000 square feet and is equipped with packaging lines
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
The company is addressing these observations
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The audit is a pre-approval inspection for three products filed from the facility
Subscribe To Our Newsletter & Stay Updated
